img

Global IBS-C Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global IBS-C Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

IBS‑C is defined as belly pain (abdominal pain) associated with constipation. The symptoms of IBS‑C are defined as long-lasting and keep coming back. Those suffering from IBS‑C also have hard or lumpy stools at least 25% of the time, and loose or watery stools less than 25% of the time.
The global IBS-C Drug market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The important driver increasing growth in the Global Irritable Bowel Syndrome with Constipation drugs Market are modern dietary habits that are having adverse effects on the human body. Some of the dietary habits leading to constipation include high intake of foods like insoluble fiber, grains, milk, fried foods, etc. Excessive intake of caffeine and alcohol increases excretion, and this loss of water through urination can also lead to IBS.
In terms of sales (consumption) side, this report focuses on the sales of IBS-C Drug by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global IBS-C Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global IBS-C Drug market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Allergan
Takeda
Sucampo Pharmaceuticals
IM HealthScience
By Type
Amitiza
Lactulose
Milk of Magnesia
LINZESS (Linaclotide)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by distribution channel, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of IBS-C Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of IBS-C Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by distribution channel, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by distribution channel and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by distribution channel and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by distribution channel, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by distribution channel and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by distribution channel and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IBS-C Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 IBS-C Drug Definition
1.2 Market by Type
1.2.1 Global IBS-C Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Amitiza
1.2.3 Lactulose
1.2.4 Milk of Magnesia
1.2.5 LINZESS (Linaclotide)
1.2.6 Others
1.3 Market Segment by Distribution Channel
1.3.1 Global IBS-C Drug Market Size Growth Rate by Distribution Channel, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global IBS-C Drug Sales
2.1 Global IBS-C Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global IBS-C Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global IBS-C Drug Revenue by Region
2.3.1 Global IBS-C Drug Revenue by Region (2018-2024)
2.3.2 Global IBS-C Drug Revenue by Region (2024-2034)
2.4 Global IBS-C Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global IBS-C Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global IBS-C Drug Sales Quantity by Region
2.6.1 Global IBS-C Drug Sales Quantity by Region (2018-2024)
2.6.2 Global IBS-C Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global IBS-C Drug Sales Quantity by Manufacturers
3.1.1 Global IBS-C Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global IBS-C Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by IBS-C Drug Sales in 2022
3.2 Global IBS-C Drug Revenue by Manufacturers
3.2.1 Global IBS-C Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global IBS-C Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by IBS-C Drug Revenue in 2022
3.3 Global IBS-C Drug Sales Price by Manufacturers
3.4 Global Key Players of IBS-C Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global IBS-C Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of IBS-C Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of IBS-C Drug, Product Offered and Application
3.8 Global Key Manufacturers of IBS-C Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global IBS-C Drug Sales Quantity by Type
4.1.1 Global IBS-C Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global IBS-C Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global IBS-C Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global IBS-C Drug Revenue by Type
4.2.1 Global IBS-C Drug Historical Revenue by Type (2018-2024)
4.2.2 Global IBS-C Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global IBS-C Drug Revenue Market Share by Type (2018-2034)
4.3 Global IBS-C Drug Price by Type
4.3.1 Global IBS-C Drug Price by Type (2018-2024)
4.3.2 Global IBS-C Drug Price Forecast by Type (2024-2034)
5 Market Size by Distribution Channel
5.1 Global IBS-C Drug Sales Quantity by Distribution Channel
5.1.1 Global IBS-C Drug Historical Sales Quantity by Distribution Channel (2018-2024)
5.1.2 Global IBS-C Drug Forecasted Sales Quantity by Distribution Channel (2024-2034)
5.1.3 Global IBS-C Drug Sales Quantity Market Share by Distribution Channel (2018-2034)
5.2 Global IBS-C Drug Revenue by Distribution Channel
5.2.1 Global IBS-C Drug Historical Revenue by Distribution Channel (2018-2024)
5.2.2 Global IBS-C Drug Forecasted Revenue by Distribution Channel (2024-2034)
5.2.3 Global IBS-C Drug Revenue Market Share by Distribution Channel (2018-2034)
5.3 Global IBS-C Drug Price by Distribution Channel
5.3.1 Global IBS-C Drug Price by Distribution Channel (2018-2024)
5.3.2 Global IBS-C Drug Price Forecast by Distribution Channel (2024-2034)
6 North America
6.1 North America IBS-C Drug Sales by Company
6.1.1 North America IBS-C Drug Revenue by Company (2018-2024)
6.1.2 North America IBS-C Drug Sales Quantity by Company (2018-2024)
6.2 North America IBS-C Drug Market Size by Type
6.2.1 North America IBS-C Drug Sales Quantity by Type (2018-2034)
6.2.2 North America IBS-C Drug Revenue by Type (2018-2034)
6.3 North America IBS-C Drug Market Size by Distribution Channel
6.3.1 North America IBS-C Drug Sales Quantity by Distribution Channel (2018-2034)
6.3.2 North America IBS-C Drug Revenue by Distribution Channel (2018-2034)
6.4 North America IBS-C Drug Market Size by Country
6.4.1 North America IBS-C Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America IBS-C Drug Revenue by Country (2018-2034)
6.4.3 North America IBS-C Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe IBS-C Drug Sales by Company
7.1.1 Europe IBS-C Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe IBS-C Drug Revenue by Company (2018-2024)
7.2 Europe IBS-C Drug Market Size by Type
7.2.1 Europe IBS-C Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe IBS-C Drug Revenue by Type (2018-2034)
7.3 Europe IBS-C Drug Market Size by Distribution Channel
7.3.1 Europe IBS-C Drug Sales Quantity by Distribution Channel (2018-2034)
7.3.2 Europe IBS-C Drug Revenue by Distribution Channel (2018-2034)
7.4 Europe IBS-C Drug Market Size by Country
7.4.1 Europe IBS-C Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe IBS-C Drug Revenue by Country (2018-2034)
7.4.3 Europe IBS-C Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China IBS-C Drug Sales by Company
8.1.1 China IBS-C Drug Sales Quantity by Company (2018-2024)
8.1.2 China IBS-C Drug Revenue by Company (2018-2024)
8.2 China IBS-C Drug Market Size by Type
8.2.1 China IBS-C Drug Sales Quantity by Type (2018-2034)
8.2.2 China IBS-C Drug Revenue by Type (2018-2034)
8.3 China IBS-C Drug Market Size by Distribution Channel
8.3.1 China IBS-C Drug Sales Quantity by Distribution Channel (2018-2034)
8.3.2 China IBS-C Drug Revenue by Distribution Channel (2018-2034)
9 APAC (excluding China)
9.1 APAC IBS-C Drug Sales by Company
9.1.1 APAC IBS-C Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC IBS-C Drug Revenue by Company (2018-2024)
9.2 APAC IBS-C Drug Market Size by Type
9.2.1 APAC IBS-C Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC IBS-C Drug Revenue by Type (2018-2034)
9.3 APAC IBS-C Drug Market Size by Distribution Channel
9.3.1 APAC IBS-C Drug Sales Quantity by Distribution Channel (2018-2034)
9.3.2 APAC IBS-C Drug Revenue by Distribution Channel (2018-2034)
9.4 APAC IBS-C Drug Market Size by Region
9.4.1 APAC IBS-C Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC IBS-C Drug Revenue by Region (2018-2034)
9.4.3 APAC IBS-C Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America IBS-C Drug Sales by Company
10.1.1 Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America IBS-C Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America IBS-C Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America IBS-C Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America IBS-C Drug Market Size by Distribution Channel
10.3.1 Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Distribution Channel (2018-2034)
10.3.2 Middle East, Africa and Latin America IBS-C Drug Revenue by Distribution Channel (2018-2034)
10.4 Middle East, Africa and Latin America IBS-C Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America IBS-C Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America IBS-C Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Allergan
11.1.1 Allergan Company Information
11.1.2 Allergan Overview
11.1.3 Allergan IBS-C Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Allergan IBS-C Drug Products and Services
11.1.5 Allergan IBS-C Drug SWOT Analysis
11.1.6 Allergan Recent Developments
11.2 Takeda
11.2.1 Takeda Company Information
11.2.2 Takeda Overview
11.2.3 Takeda IBS-C Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Takeda IBS-C Drug Products and Services
11.2.5 Takeda IBS-C Drug SWOT Analysis
11.2.6 Takeda Recent Developments
11.3 Sucampo Pharmaceuticals
11.3.1 Sucampo Pharmaceuticals Company Information
11.3.2 Sucampo Pharmaceuticals Overview
11.3.3 Sucampo Pharmaceuticals IBS-C Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Sucampo Pharmaceuticals IBS-C Drug Products and Services
11.3.5 Sucampo Pharmaceuticals IBS-C Drug SWOT Analysis
11.3.6 Sucampo Pharmaceuticals Recent Developments
11.4 IM HealthScience
11.4.1 IM HealthScience Company Information
11.4.2 IM HealthScience Overview
11.4.3 IM HealthScience IBS-C Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 IM HealthScience IBS-C Drug Products and Services
11.4.5 IM HealthScience IBS-C Drug SWOT Analysis
11.4.6 IM HealthScience Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 IBS-C Drug Value Chain Analysis
12.2 IBS-C Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 IBS-C Drug Production Mode & Process
12.4 IBS-C Drug Sales and Marketing
12.4.1 IBS-C Drug Sales Channels
12.4.2 IBS-C Drug Distributors
12.5 IBS-C Drug Customers
13 Market Dynamics
13.1 IBS-C Drug Industry Trends
13.2 IBS-C Drug Market Drivers
13.3 IBS-C Drug Market Challenges
13.4 IBS-C Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global IBS-C Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Amitiza
Table 3. Major Manufacturers of Lactulose
Table 4. Major Manufacturers of Milk of Magnesia
Table 5. Major Manufacturers of LINZESS (Linaclotide)
Table 6. Major Manufacturers of Others
Table 7. Global IBS-C Drug Market Size Growth Rate (CAGR) by Distribution Channel, 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global IBS-C Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global IBS-C Drug Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global IBS-C Drug Revenue Market Share by Region (2018-2024)
Table 11. Global IBS-C Drug Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global IBS-C Drug Revenue Market Share by Region (2024-2034)
Table 13. Global IBS-C Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 14. Global IBS-C Drug Sales by Region (2018-2024) & (K Units)
Table 15. Global IBS-C Drug Sales Market Share by Region (2018-2024)
Table 16. Global IBS-C Drug Sales by Region (2024-2034) & (K Units)
Table 17. Global IBS-C Drug Sales Market Share by Region (2024-2034)
Table 18. Global IBS-C Drug Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 19. Global IBS-C Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 20. Global IBS-C Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 21. Global IBS-C Drug Revenue Share by Manufacturers (2018-2024)
Table 22. Global IBS-C Drug Price by Manufacturers 2018-2024 (USD/Unit)
Table 23. Global Key Players of IBS-C Drug, Industry Ranking, 2021 VS 2022
Table 24. Global IBS-C Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global IBS-C Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS-C Drug as of 2022)
Table 26. Global Key Manufacturers of IBS-C Drug, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of IBS-C Drug, Product Offered and Application
Table 28. Global Key Manufacturers of IBS-C Drug, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global IBS-C Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 31. Global IBS-C Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 32. Global IBS-C Drug Sales Quantity Share by Type (2018-2024)
Table 33. Global IBS-C Drug Sales Quantity Share by Type (2024-2034)
Table 34. Global IBS-C Drug Revenue by Type (2018-2024) & (US$ Million)
Table 35. Global IBS-C Drug Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global IBS-C Drug Revenue Share by Type (2018-2024)
Table 37. Global IBS-C Drug Revenue Share by Type (2024-2034)
Table 38. IBS-C Drug Price by Type (2018-2024) & (USD/Unit)
Table 39. Global IBS-C Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 40. Global IBS-C Drug Sales Quantity by Distribution Channel (2018-2024) & (K Units)
Table 41. Global IBS-C Drug Sales Quantity by Distribution Channel (2024-2034) & (K Units)
Table 42. Global IBS-C Drug Sales Quantity Share by Distribution Channel (2018-2024)
Table 43. Global IBS-C Drug Sales Quantity Share by Distribution Channel (2024-2034)
Table 44. Global IBS-C Drug Revenue by Distribution Channel (2018-2024) & (US$ Million)
Table 45. Global IBS-C Drug Revenue by Distribution Channel (2024-2034) & (US$ Million)
Table 46. Global IBS-C Drug Revenue Share by Distribution Channel (2018-2024)
Table 47. Global IBS-C Drug Revenue Share by Distribution Channel (2024-2034)
Table 48. IBS-C Drug Price by Distribution Channel (2018-2024) & (USD/Unit)
Table 49. Global IBS-C Drug Price Forecast by Distribution Channel (2024-2034) & (USD/Unit)
Table 50. North America IBS-C Drug Revenue by Company (2018-2024) & (US$ Million)
Table 51. North America IBS-C Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 52. North America IBS-C Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 53. North America IBS-C Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 54. North America IBS-C Drug Revenue by Type (2018-2024) & (US$ Million)
Table 55. North America IBS-C Drug Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America IBS-C Drug Sales Quantity by Distribution Channel (2018-2024) & (K Units)
Table 57. North America IBS-C Drug Sales Quantity by Distribution Channel (2024-2034) & (K Units)
Table 58. North America IBS-C Drug Revenue by Distribution Channel (2018-2024) & (US$ Million)
Table 59. North America IBS-C Drug Revenue by Distribution Channel (2024-2034) & (US$ Million)
Table 60. North America IBS-C Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 61. North America IBS-C Drug Revenue by Country (2018-2024) & (US$ Million)
Table 62. North America IBS-C Drug Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America IBS-C Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 64. North America IBS-C Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 65. Europe IBS-C Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 66. Europe IBS-C Drug Revenue by Company (2018-2024) & (US$ Million)
Table 67. Europe IBS-C Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 68. Europe IBS-C Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 69. Europe IBS-C Drug Revenue by Type (2018-2024) & (US$ Million)
Table 70. Europe IBS-C Drug Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe IBS-C Drug Sales Quantity by Distribution Channel (2018-2024) & (K Units)
Table 72. Europe IBS-C Drug Sales Quantity by Distribution Channel (2024-2034) & (K Units)
Table 73. Europe IBS-C Drug Revenue by Distribution Channel (2018-2024) & (US$ Million)
Table 74. Europe IBS-C Drug Revenue by Distribution Channel (2024-2034) & (US$ Million)
Table 75. Europe IBS-C Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 76. Europe IBS-C Drug Revenue by Country (2018-2024) & (US$ Million)
Table 77. Europe IBS-C Drug Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe IBS-C Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 79. Europe IBS-C Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 80. China IBS-C Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 81. China IBS-C Drug Revenue by Company (2018-2024) & (US$ Million)
Table 82. China IBS-C Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 83. China IBS-C Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 84. China IBS-C Drug Revenue by Type (2018-2024) & (US$ Million)
Table 85. China IBS-C Drug Revenue by Type (2024-2034) & (US$ Million)
Table 86. China IBS-C Drug Sales Quantity by Distribution Channel (2018-2024) & (K Units)
Table 87. China IBS-C Drug Sales Quantity by Distribution Channel (2024-2034) & (K Units)
Table 88. China IBS-C Drug Revenue by Distribution Channel (2018-2024) & (US$ Million)
Table 89. China IBS-C Drug Revenue by Distribution Channel (2024-2034) & (US$ Million)
Table 90. APAC IBS-C Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 91. APAC IBS-C Drug Revenue by Company (2018-2024) & (US$ Million)
Table 92. APAC IBS-C Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 93. APAC IBS-C Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 94. APAC IBS-C Drug Revenue by Type (2018-2024) & (US$ Million)
Table 95. APAC IBS-C Drug Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC IBS-C Drug Sales Quantity by Distribution Channel (2018-2024) & (K Units)
Table 97. APAC IBS-C Drug Sales Quantity by Distribution Channel (2024-2034) & (K Units)
Table 98. APAC IBS-C Drug Revenue by Distribution Channel (2018-2024) & (US$ Million)
Table 99. APAC IBS-C Drug Revenue by Distribution Channel (2024-2034) & (US$ Million)
Table 100. APAC IBS-C Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 101. APAC IBS-C Drug Revenue by Region (2018-2024) & (US$ Million)
Table 102. APAC IBS-C Drug Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC IBS-C Drug Sales Quantity by Region (2018-2024) & (K Units)
Table 104. APAC IBS-C Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 105. Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America IBS-C Drug Revenue by Company (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 109. Middle East, Africa and Latin America IBS-C Drug Revenue by Type (2018-2024) & (US$ Million)
Table 110. Middle East, Africa and Latin America IBS-C Drug Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Distribution Channel (2018-2024) & (K Units)
Table 112. Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Distribution Channel (2024-2034) & (K Units)
Table 113. Middle East, Africa and Latin America IBS-C Drug Revenue by Distribution Channel (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America IBS-C Drug Revenue by Distribution Channel (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America IBS-C Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America IBS-C Drug Revenue by Country (2018-2024) & (US$ Million)
Table 117. Middle East, Africa and Latin America IBS-C Drug Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 119. Middle East, Africa and Latin America IBS-C Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 120. Allergan Company Information
Table 121. Allergan Description and Overview
Table 122. Allergan IBS-C Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 123. Allergan IBS-C Drug Product and Services
Table 124. Allergan IBS-C Drug SWOT Analysis
Table 125. Allergan Recent Developments
Table 126. Takeda Company Information
Table 127. Takeda Description and Overview
Table 128. Takeda IBS-C Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 129. Takeda IBS-C Drug Product and Services
Table 130. Takeda IBS-C Drug SWOT Analysis
Table 131. Takeda Recent Developments
Table 132. Sucampo Pharmaceuticals Company Information
Table 133. Sucampo Pharmaceuticals Description and Overview
Table 134. Sucampo Pharmaceuticals IBS-C Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 135. Sucampo Pharmaceuticals IBS-C Drug Product and Services
Table 136. Sucampo Pharmaceuticals IBS-C Drug SWOT Analysis
Table 137. Sucampo Pharmaceuticals Recent Developments
Table 138. IM HealthScience Company Information
Table 139. IM HealthScience Description and Overview
Table 140. IM HealthScience IBS-C Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 141. IM HealthScience IBS-C Drug Product and Services
Table 142. IM HealthScience IBS-C Drug SWOT Analysis
Table 143. IM HealthScience Recent Developments
Table 144. Key Raw Materials Lists
Table 145. Raw Materials Key Suppliers Lists
Table 146. IBS-C Drug Distributors List
Table 147. IBS-C Drug Customers List
Table 148. IBS-C Drug Market Trends
Table 149. IBS-C Drug Market Drivers
Table 150. IBS-C Drug Market Challenges
Table 151. IBS-C Drug Market Restraints
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. IBS-C Drug Product Picture
Figure 2. Global IBS-C Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global IBS-C Drug Market Share by Type in 2022 & 2034
Figure 4. Amitiza Product Picture
Figure 5. Lactulose Product Picture
Figure 6. Milk of Magnesia Product Picture
Figure 7. LINZESS (Linaclotide) Product Picture
Figure 8. Others Product Picture
Figure 9. Global IBS-C Drug Market Size Growth Rate by Distribution Channel, 2018 VS 2022 VS 2034 (US$ Million)
Figure 10. Global IBS-C Drug Market Share by Distribution Channel in 2022 & 2034
Figure 11. Hospital Pharmacies
Figure 12. Retail Pharmacies
Figure 13. Online Pharmacies
Figure 14. IBS-C Drug Report Years Considered
Figure 15. Global IBS-C Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global IBS-C Drug Revenue 2018-2034 (US$ Million)
Figure 17. Global IBS-C Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global IBS-C Drug Sales Quantity 2018-2034 (K Units)
Figure 19. Global IBS-C Drug Sales Quantity Market Share by Region (2018-2024)
Figure 20. Global IBS-C Drug Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America IBS-C Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. North America IBS-C Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe IBS-C Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. Europe IBS-C Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China IBS-C Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. China IBS-C Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC IBS-C Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. APAC IBS-C Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America IBS-C Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. Middle East, Africa and Latin America IBS-C Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by IBS-C Drug Sales Quantity in 2022
Figure 32. The Top 10 and Top 5 Players Market Share by IBS-C Drug Revenue in 2022
Figure 33. IBS-C Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global IBS-C Drug Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global IBS-C Drug Revenue Market Share by Type (2018-2034)
Figure 36. Global IBS-C Drug Sales Quantity Market Share by Distribution Channel (2018-2034)
Figure 37. Global IBS-C Drug Revenue Market Share by Distribution Channel (2018-2034)
Figure 38. North America IBS-C Drug Revenue Market Share by Company in 2022
Figure 39. North America IBS-C Drug Sales Quantity Market Share by Company in 2022
Figure 40. North America IBS-C Drug Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America IBS-C Drug Revenue Market Share by Type (2018-2034)
Figure 42. North America IBS-C Drug Sales Quantity Market Share by Distribution Channel (2018-2034)
Figure 43. North America IBS-C Drug Revenue Market Share by Distribution Channel (2018-2034)
Figure 44. North America IBS-C Drug Revenue Share by Country (2018-2034)
Figure 45. North America IBS-C Drug Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Canada IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Europe IBS-C Drug Sales Quantity Market Share by Company in 2022
Figure 49. Europe IBS-C Drug Revenue Market Share by Company in 2022
Figure 50. Europe IBS-C Drug Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe IBS-C Drug Revenue Market Share by Type (2018-2034)
Figure 52. Europe IBS-C Drug Sales Quantity Market Share by Distribution Channel (2018-2034)
Figure 53. Europe IBS-C Drug Revenue Market Share by Distribution Channel (2018-2034)
Figure 54. Europe IBS-C Drug Revenue Share by Country (2018-2034)
Figure 55. Europe IBS-C Drug Sales Quantity Share by Country (2018-2034)
Figure 56. Germany IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 57. France IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Italy IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Russia IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 61. China IBS-C Drug Sales Quantity Market Share by Company in 2022
Figure 62. China IBS-C Drug Revenue Market Share by Company in 2022
Figure 63. China IBS-C Drug Sales Quantity Market Share by Type (2018-2034)
Figure 64. China IBS-C Drug Revenue Market Share by Type (2018-2034)
Figure 65. China IBS-C Drug Sales Quantity Market Share by Distribution Channel (2018-2034)
Figure 66. China IBS-C Drug Revenue Market Share by Distribution Channel (2018-2034)
Figure 67. APAC IBS-C Drug Sales Quantity Market Share by Company in 2022
Figure 68. APAC IBS-C Drug Revenue Market Share by Company in 2022
Figure 69. APAC IBS-C Drug Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC IBS-C Drug Revenue Market Share by Type (2018-2034)
Figure 71. APAC IBS-C Drug Sales Quantity Market Share by Distribution Channel (2018-2034)
Figure 72. APAC IBS-C Drug Revenue Market Share by Distribution Channel (2018-2034)
Figure 73. APAC IBS-C Drug Revenue Share by Region (2018-2034)
Figure 74. APAC IBS-C Drug Sales Quantity Share by Region (2018-2034)
Figure 75. Japan IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 79. India IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America IBS-C Drug Sales Quantity Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America IBS-C Drug Revenue Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America IBS-C Drug Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America IBS-C Drug Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America IBS-C Drug Sales Quantity Market Share by Distribution Channel (2018-2034)
Figure 85. Middle East, Africa and Latin America IBS-C Drug Revenue Market Share by Distribution Channel (2018-2034)
Figure 86. Middle East, Africa and Latin America IBS-C Drug Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America IBS-C Drug Revenue Share by Country (2018-2034)
Figure 88. Brazil IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Israel IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries IBS-C Drug Revenue (2018-2034) & (US$ Million)
Figure 93. IBS-C Drug Value Chain
Figure 94. IBS-C Drug Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed